Schott Pharma (stylized as SCHOTT Pharma) is a provider of drug containment solutions and delivery systems for injectable drugs.[2][3] Originally a subsidiary of the glass manufacturer Otto Schott, the company went private and subsequently entered the Frankfurst Stock Exchange in 2023.[4] Headquartered in Mainz, Germany,[5][6] the company operates in 14 countries.[7]
Company type | KGaA with Aktiengesellschaft as partner with unlimited liability |
---|---|
FWB: 1SXP | |
ISIN | DE000A3ENQ51 |
Industry | Healthcare |
Founded | August 1, 2022 |
Headquarters | Mainz, Germany |
Key people | Andreas Reisse, CEO Almuth Steinkühler, CFO |
Products | Pharmaceutical drug containment and delivery systems |
Revenue | €899 million (2022/2023)[1] |
Owner | Schott AG |
Number of employees | 4,646 (as of September 30, 2023)[1] |
Divisions |
|
Website | schott-pharma |
History
editIn 1887, Otto Schott developed borosilicate glass, a form of glassware used to reagent bottles and flasks. From 1911, Schott manufactured borosilicate glass tubing for the production of pharmaceutical ampoules and vials.[8]
Schott Pharma was established as a standalone company in 2022 under the name Schott Pharma AG & Co. KGaA[9][6] through an equity carve-out (or spin-off) from Schott AG, a manufacturer of specialty glass and glass-ceramics.[10][11]In the same year, the company announced their plans to present an IPO, but this was reportedly postponed to 2023 due to the Russian invasion of Ukraine.[5]
In June 2023, Schott Pharma announced plans to hold the IPO in September 2023.[12] This plan was enacted in September, with Schott Pharma going public on the Frankfurt Stock Exchange.[13] The IPO was initially priced at 27€ per share,[14][15] and a potential valuation of up to 4.1 billion euros,[16] but increased the share price to 30€ the following day.[17][13] The IPO was the largest of the year in Germany.[18][19] In December 2023, Schott Pharma was included in the SDAX.[20] In September 2024, Schott Pharma announced their impending inclusion on the MDAX.[21]
Production & Manufacturing
editThis section needs expansion. You can help by adding to it. (June 2024) |
The company is headquartered in Mainz and operates in 16 locations across 14 countries.[22]
Europe
edit- Müllhein, Germany (Müllheim Production and Technology Centre)[23][24]
- Hungary[25][26][27]
- Switzerland[6][27]
- Serbia[26][28]
North America
editSouth America
editAsia
edit- China[25]
Products
editSchott Pharma develops and manufactures drug containment solutions and delivery systems for injectable drugs, which it supplies to companies in the biotechnology and pharmaceutical industries.[31]
Its business is divided into two divisions:
- Drug Containment Solutions: pharmaceutical vials, cartridges, and glass ampoules[32]
- Drug Delivery Systems: prefillable glass syringes and syringes made from Cyclic olefin copolymers (COC), suitable for deep-cold medications.[33]
Governance
editSchott Pharma is a subsidiary of SCHOTT AG, who has controlling shares of 77%(as of 2023: 77%).[19][17] SCHOTT AG is owned by the Carl Zeiss Foundation.[25]
Schott Pharma was listed on the Frankfurt Stock Exchange's SDAX in 2023.
This section needs expansion. You can help by adding to it. (June 2024) |
Parent Company Board of Directors
edit- Frank Heinricht (CEO of Schott AG) [23]
- Almuth Steinkühler (Chief Financial Officer of Schott AG)[34]
Independent Supervisory Board
editIn 2023 SCHOTT AG appointed a Supervisory Board for the subsidiary Schott Parma AG as follows:[35][36]
- Peter Goldschmidt, (Chairman)
- Dr. Wolfgang Wienand (Chairman of the Executive Board of Siegfried Holding AG)
- Eva Kienle (CFO of KWS Saat SE & Co. KGaA)
- Ann-Kristin Erkens (Corporate Senior Vice President, Financial and Business Controlling at Henkel Adhesive Technologies)
- Christine Wening (employee stakeholder)
- Mario Just (employee stakeholder)
Financial Results
editThis section needs expansion. You can help by adding to it. (June 2024) |
2022/23 | 2023/24 | ||
---|---|---|---|
Turnover | |||
Net Profit | |||
References
edit- ^ a b SCHOTT Pharma Annual Report 2022/2023 (accessed February 08, 2024)
- ^ Kansteiner, Fraiser (2023-12-23). "Glass specialist Schott Pharma touts 2023 sales growth, Serbia expansion and hiring plans". Fierce Pharma. Retrieved 2024-04-08.
- ^ "EQS-News: SCHOTT Pharma bestätigt Prognose für das Geschäftsjahr 2024 anlässlich seiner Q2-Ergebnisse; Geschäftsjahr 2025 durch geringeres Wachstum bei Spritzen beeinflusst" [EQS-News: SCHOTT Pharma confirms forecast for the 2024 financial year on the occasion of its Q2 results; financial year 2025 influenced by lower growth in syringes]. 4Investors.de (in German). 2024-05-14. Retrieved 2024-06-24.
- ^ Rauffmann, Theresa (2024-06-27). "Abhängigkeit vom Geschäft mit Diätspritzen wird zum Problem" [Dependence on the business with diet syringes becomes a problem]. www.handelsblatt.com. Retrieved 2024-09-18.
- ^ a b Ibrahim, Samir (2023-09-28). "Schott Pharma startet erfolgreich an der Frankfurter Börse". tagesschau.de (in German). Retrieved 2024-06-24.
- ^ a b c Nünchert, Ike (2022-08-03). "SCHOTT Pharma: Carve-Out für ein mögliches IPO" [SCHOTT Pharma: Carve-Out for a possible IPO]. Going Public. Retrieved 2024-06-24.
- ^ "Größter Börsengang in 2023: So hat sich die SCHOTT Pharma-Aktie seit ihrem IPO entwickelt - und so könnte es in 2024 nun weitergehen". finanzen.net. 2024-01-24. Retrieved 2024-02-28.
- ^ "Impfstoff-Ampullen – Rohrglas für Lebensretter - VBG Spezial". glaskeramik.org. VBG. 2021-07-04. Retrieved 2024-02-28.
- ^ Dunleavy, Kevin (2023-09-06). "After one year as standalone business, glassmaker Schott Pharma sets course for IPO". Fierce Pharma. Retrieved 2024-06-24.
- ^ Kansteiner, Fraiser (2022-01-08). "Glass maker Schott's pharma business sets out on its own. Will an IPO follow?". Fierce Pharma. Retrieved 2024-02-28.
- ^ Landsteiner, Fraiser (2022-08-01). "Glass maker Schott's pharma business sets out on its own. Will an IPO follow?". Fierce Pharma. Retrieved 2024-06-24.
- ^ Wilkes, William; Gopinath, Swetha (2023-06-22). "Schott to Hold IPO of Medical Glassware Unit in September: Bloomberg.com". Bloomberg.com: N.PAG–N.PAG.
- ^ a b "Schott Pharma trades up following biggest German IPO since Porsche: Global Capital". Global Capital: N.PAG–N.PAG. 2023-10-16.
- ^ Gopinath, Swetha (2023-09-28). "Germany's Schott Raises €813 Million in IPO of Medical-Glass Arm". www.bloomberg.com. Retrieved 2024-06-24.
- ^ gsp (2023-09-29). "Schott Pharma geht mit Freshfields an die Frankfurter Börse" [Schott Pharma goes to the Frankfurt Stock Exchange with Freshfields]. Extrajournal.Net (in German). Retrieved 2024-06-24.
- ^ "Schott Pharma prices IPO at 27 euros per share". Reuters. 2023-09-27. Retrieved 2024-06-24.
- ^ a b "SCHOTT Pharma feiert erfolgreiches Börsendebüt: Erstkurs über Ausgabepreis" [SCHOTT Pharma celebrates successful stock market debut: First price on issue price]. Finanzen Net (in German). 2023-09-28. Retrieved 2024-06-24.
- ^ Farr, Emma-Victoria; Mayo Cerqueiro, Pablo (2023-09-28). "Schott Pharma shares jump 16% in Frankfurt trading debut". reuters.com. Reuters. Retrieved 2024-02-28.
- ^ a b "Schott Pharma startet erfolgreich an der Börse". tagesschau.de. 2023-09-28. Retrieved 2024-02-28.
- ^ Ingerl, Christian (2023-12-13). "Profitabler Small Cap: Zulieferer Schott Pharma bald im SDax". Capital. Retrieved 2024-02-28.
- ^ Adams, Dominik (2024-09-06). "Wachstum und MDAX-Aufnahme: Schott Pharma auf Erfolgskurs" [Growth and MDAX recording: Schott Pharma on the road to success]. stock3 (in German). Retrieved 2024-09-18.
- ^ "Größter Börsengang in 2023: So hat sich die SCHOTT Pharma-Aktie seit ihrem IPO entwickelt - und so könnte es in 2024 nun weitergehen". finanzen.net. 2024-01-24. Retrieved 2024-02-28.
- ^ a b Zeitung, Badische (2022-12-02). "SCHOTT Pharma: Ein globales Kompetenzzentrum in Müllheim". Badische Zeitung (in German). Retrieved 2024-06-24.
- ^ Schlegel, Marion (2023-12-19). "SDAX-Neuling Schott Pharma gibt ordentlich Gas: Zahlen kommen gut an". www.deraktionaer.de (in German). Retrieved 2024-06-24.
- ^ a b c "SCHOTT Pharma baut Produktion in China und Ungarn aus – ZWP online – das Nachrichtenportal für die Dentalbranche". www.zwp-online.info (in German). 2022-09-22. Retrieved 2024-06-24.
- ^ a b "SCHOTT: solides Ergebnis trotz konjunktureller Herausforderungen – ZWP online – das Nachrichtenportal für die Dentalbranche" [SCHOTT: solid result despite economic challenges]. www.zwp-online.info (in German). 2024-02-12. Retrieved 2024-06-24.
- ^ a b Herpai, Gergely (2024-07-12). "Schott Pharma's HUF 28 bln Investment Boosts Hungarian Pharmaceutical Manufacturing: Budapest Business Journal". Budapest Business Journal. 32 (14): 8–8.
- ^ "Schott Pharma Begins Construction on Serbia Plant: American Ceramic Society Bulletin". American Ceramic Society Bulletin. 103 (5): 49–49. July 2024.
- ^ a b Schott (2024-03-18). "SCHOTT Pharma to Expand in the U.S. with New Prefillable Syringe Manufacturing Facility in Wilson, North Carolina: Business Wire (English)". Business Wire (English).
- ^ Anselmo, Joelle (2024-03-27). "Schott Pharma to build $371M syringe factory: Construction Dive". Construction Dive: N.PAG–N.PAG.
- ^ SCHOTT Pharma Annual Report 2022/2023, SCHOTT Pharma, p. 14, retrieved 2024-02-28
- ^ Kaiser, Lea (2023-10-24). "Next generation pharma glass: SCHOTT AG launches FIOLAX® Pro Glass tubing". BusinessWire. Retrieved 2024-06-24.
- ^ "Schott Pharma rolls out pre-filled polymer syringes for deep-cold medication". NS Medical Devices. 2023-05-18. Retrieved 2024-02-28.
- ^ Kolf, Ingo (2024-05-15). "Kurs bricht ein: Schott Pharma: Trübe Aussichten führen zu drastischem Kurseinbruch". FinanzNachrichten.de (in German). Retrieved 2024-06-24.
- ^ Mills, Jess (2023-05-02). "Schott appoints Supervisory Board of Schott Pharma". Glass International. Retrieved 2024-06-24.
- ^ "SCHOTT bestellt Aufsichtsrat der SCHOTT Pharma AG" [SCHOTT appoints Supervisory Board of SCHOTT Pharma AG]. ZWP-online. 2023-05-02. Retrieved 2024-06-24.